Business Wire

NY-MORROW-SODALI

26.4.2022 15:02:06 CEST | Business Wire | Press release

Share
Morrow Sodali Secures Majority Investment From TPG Growth

Morrow Sodali, the leading global shareholder engagement and governance advisory firm, announced today that TPG Growth, the middle market and growth equity platform of alternative asset firm TPG, has acquired a majority stake in the company. The partnership with TPG will significantly advance Morrow Sodali’s mission of providing clients worldwide with unrivaled strategic advice and comprehensive support, enabling them to maximize value and expertly manage stakeholder relations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005374/en/

TPG’s investment coincides with Morrow Sodali’s 50th anniversary, which the company is celebrating with a series of special initiatives centered on the theme of “Building Together”. Throughout the year, Morrow Sodali will highlight the Company’s best-in-class expertise on emerging global trends in shareholder engagement matters impacting corporations, including ESG reporting, sustainability, climate change, board composition and evaluation, succession planning, executive compensation, shareholder activism and investor engagement.

Alvise Recchi, Chief Executive Officer of Morrow Sodali, said: "We are thrilled to become a TPG portfolio company. Joining forces with an organization of TPG's strength and breadth will allow us to further enhance our market leadership position, forged over decades of guiding clients through every critical trend impacting corporations, shareholders, and the financial markets. Our focus is on delivering value creation and as we move forward with TPG’s backing, we’ll grow that value for our clients, especially as they increase their focus on corporate purpose and the goals of diversity, inclusiveness, and sustainability.”

Ransom Langford, Partner at TPG, added: "Morrow Sodali’s differentiated ability to deliver results for its diverse set of clients, combined with a commitment to its values of integrity, excellence, collaboration, innovation and respect creates a unique opportunity for our partnership. As the focus on ESG continues to increase amongst companies and investors alike, Morrow Sodali has established itself as a trusted partner and global leader in proactive and trusted shareholder engagement. We look forward to working with the Morrow Sodali team to continue investing in the business’ extensive breadth of services and capabilities across the shareholder lifecycle."

Morrow Sodali recently secured the #1 position in 2021 M&A league tables released by both Mergermarket and The Deal. Morrow Sodali has made several highly strategic, global acquisitions and personnel investments, and, with the support of TPG, expects to accelerate those efforts.

ABOUT MORROW SODALI

Morrow Sodali is a global corporate advisory firm focused on shareholder engagement. The Company provides clients with comprehensive services relating to corporate governance , diversity equity & inclusion, sustainability, proxy solicitation , capital markets intelligence , shareholder and bondholder engagement, M&A , shareholder activism and contested situations .

Headquartered in New York and with offices in London, Sydney, Buenos Aires, Frankfurt, Hong Kong, Madrid, Melbourne, Paris, Rome, Sao Paolo, Seoul, Stamford, Toyko and Toronto, Morrow Sodali serves more than 850 clients in 80+ countries, including many of the world’s largest multinational corporations. Clients include publicly-listed and private companies, mutual fund groups, stock exchanges and membership associations. For more information about Morrow Sodali, please visit www.morrowsodali.com .

ABOUT TPG GROWTH

TPG Growth is the middle market and growth equity investment platform of TPG, the global alternative asset firm. With approximately $14.7 billion of assets under management, TPG Growth targets investments in a broad range of industries and geographies. TPG Growth has the deep sector knowledge, operational resources, and global experience to drive value creation, and help companies reach their full potential. The platform is backed by the resources of TPG, which has approximately $114 billion of assets under management. For more information, please visit www.tpg.com or on Twitter @TPG.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye